India rejects United States firm patent application for six month tuberculosis treatment
- India's Patent Office rejected US-based TB Alliance’s patent application for a tuberculosis drug regimen.
- The rejected application covered BPaL, an oral three-drug combination treating drug-resistant tuberculosis in six months.
- Patent officials rejected the application because the drug combination lacked novelty and genuine inventive steps.
- The decision enables generic manufacturers to produce affordable medicines, improving patient access across India.
Source: hindustantimes.com
Get 100 stories a day on the app
Read, watch & listen · Free on iOS & Android
